A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Latest Information Update: 26 Sep 2024
Price :
$35 *
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ADORE; ADOREXT
- Sponsors Ferrer
- 06 Sep 2024 Status changed from active, no longer recruiting to completed.
- 30 Mar 2024 This trial has been Completed in Portugal, According to European Clinical Trials Database record.
- 11 Feb 2024 This trial has been Completed in Sweden, According to European Clinical Trials Database record.